/ RESORCE Trial positive in second line for HCC

RESORCE Trial (REgorafenib after SORafenib in patients with hepatoCEllular carcinoma) has been positive in terms of overall survival for patients who progressed, and are tolerant, on sorafenib therapy.

Today Prof Bruix will be presenting results at ESMO (European Society of Medical Oncology). You can watch him on streaming from 17.40h GMT + 1. Further details will be published on twitter @BCLC_group
Thursday June 30, 2016